Combining cancer vaccines with chemotherapy

被引:14
作者
Chong, G [1 ]
Morse, MA [1 ]
机构
[1] Duke Univ, Med Ctr, Div Med Oncol, Duke S Clin, Durham, NC 27710 USA
关键词
Fas-ligand; lymphopenia; regulatory T cell; suppressor T cell;
D O I
10.1517/14656566.6.16.2813
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Clinical experience is now demonstrating the efficacy of combining chemotherapy and targeted therapies. Although the combination of chemotherapy and immunotherapy would at first seem to be counterproductive, supportive preclinical and clinical data have revealed that cyclophosphamide, gemcitabine and doxorubicin enhance the efficacy of vaccines when used as a form of 'pretreatment'. Possible mechanisms of action include inhibition of regulatory T cells, enhancement of antigen presentation by tumours, or some yet unknown method. As such, more preclinical and clinical trials are needed to explore the synergistic effects of chemotherapy combined with immunotherapy, particularly the proper dose and timing of chemotherapy.
引用
收藏
页码:2813 / 2820
页数:8
相关论文
共 58 条
  • [1] Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine
    Berd, D
    Sato, T
    Maguire, HC
    Kairys, J
    Mastrangelo, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) : 403 - 415
  • [2] BERD D, 1984, CANCER RES, V44, P5439
  • [3] Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes
    Bergmann-Leitner, ES
    Abrams, SI
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 50 (09) : 445 - 455
  • [4] Cancer immunotherapy: A treatment for the masses
    Blattman, JN
    Greenberg, PD
    [J]. SCIENCE, 2004, 305 (5681) : 200 - 205
  • [5] The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration
    Casati, A
    Zimmermann, VS
    Benigni, F
    Bertilaccio, MTS
    Bellone, M
    Mondino, A
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (06) : 3317 - 3325
  • [6] Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro
    Correale, P
    Aquino, A
    Giuliani, A
    Pellegrini, M
    Micheli, L
    Cusi, MG
    Nencini, C
    Petrioli, R
    Prete, S
    De Vecchis, L
    Turriziani, M
    Giorgi, G
    Bonmassar, E
    Francini, G
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (04) : 437 - 445
  • [7] Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Dudley, ME
    Wunderlich, JR
    Yang, JC
    Sherry, RM
    Topalian, SL
    Restifo, NP
    Royal, RE
    Kammula, U
    White, DE
    Mavroukakis, SA
    Rogers, LJ
    Gracia, GJ
    Jones, SA
    Mangiameli, DP
    Pelletier, MM
    Gea-Banacloche, J
    Robinson, MR
    Berman, DM
    Filie, AC
    Abati, A
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2346 - 2357
  • [8] EHRKE MJ, 1986, CANCER RES, V46, P54
  • [9] Leveraging the activity of tumor vaccines with cytotoxic chemotherapy
    Emens, LA
    Jaffee, EM
    [J]. CANCER RESEARCH, 2005, 65 (18) : 8059 - 8064
  • [10] Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
    Emens, LA
    Reilly, RT
    Jaffee, EM
    [J]. ENDOCRINE-RELATED CANCER, 2005, 12 (01) : 1 - 17